A randomized controlled trial of ivabradine in patients with acute myocardial infarction related cardiogenic shock

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Acute myocardial infarction-related cardiogenic shock (AMI-CS) frequently presents with tachycardia.
• Tachycardia in AMI-CS exacerbates myocardial oxygen demand and complicates the use of mechanical circulatory support.
• Ivabradine is a potential therapeutic agent for heart rate (HR) reduction without significant hemodynamic compromise.

Purpose of the Study:

• To evaluate the efficacy of ivabradine in reducing HR in patients experiencing AMI-CS with tachycardia.
• To assess the impact of ivabradine on other hemodynamic parameters, including cardiac index (CI), in this patient population.

Main Methods:

• A single-center, open-label, randomized clinical trial was conducted.
• Included patients diagnosed with AMI-CS and HR > 100 beats per minute (BPM).
• HR, CI, and other hemodynamic variables were measured via pulmonary flotation catheter at multiple time points post-randomization.

Main Results:

• A total of 12 patients were randomized; 6 received ivabradine plus standard therapy, and 6 received standard therapy alone.
• Statistically significant HR reduction was observed at 12 hours (p=0.003) and 48 hours (p=0.029) in the ivabradine group.
• No significant differences were found in CI, other hemodynamic parameters, hospital stay, or mortality between the groups.

Conclusions:

• Ivabradine administration in patients with AMI-CS and tachycardia leads to a significant decrease in heart rate.
• The observed HR reduction occurred without adverse effects on other measured hemodynamic parameters.
• Ivabradine represents a promising therapeutic option for managing tachycardia in AMI-CS.